Compare BridgeBio Pharma Inc (BBIO) vs Moody's Corporation (MCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Moody's Corporation — how do they compare? BridgeBio Pharma Inc trades at $84.12 (market cap $16.46B), while Moody's Corporation trades at $493.7 (market cap $86.42B). The key difference: Moody's Corporation is far larger — about 5.3× BridgeBio Pharma Inc's market cap, and Moody's Corporation pays a 0.83% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | MCO | |
|---|---|---|
Market Cap | $16.46B | $86.42B |
Sector | Health | Financials |
52-Week High | $90.17 | $539.61 |
52-Week Low | $44.81 | $412.23 |
Enterprise Value | $18.02B | $92.22B |
Dividend Yield | — | 0.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
MCO trades at $495.72, up 1.73% today, with strong technical momentum as price hovers near pivot point resistance at $496. The company demonstrates robust fundamentals with 31.69% net margins and consistent earnings beats, while recent AI platform expansions signal growth initiatives. Analyst consensus remains bullish with a $539.40 price target, though valuation multiples appear elevated.
Outlook remains positive given earnings momentum and strategic AI investments, but high P/E of 35.56 presents valuation risk. Key catalysts include Q2 2026 earnings release on July 22, while regulatory scrutiny and debt market sensitivity represent ongoing headwinds for the credit ratings leader.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →
